Redeye shares its preview of Sedana Medical’s Q4 2023e results, due February 15.
Bishopsgate looks highly complementary, ... ...provides diversification, and is accretive We are opt...
Market-leading white-label software provider for takeaway restaurants 13% ARR CAGR and 11pp EBITDA m...
Q4e: first quarter since Q4'21 with positive y-o-y EBITA growth Gradual margin improvement expected ...
DT’s Q4 results topped estimates as costs remained under control while SBU continued to drive growth...
Redeye’s first comments follow this morning’s Q4 report from Tagmaster.
SRV’s current low risk backlog will support it through the tougher market with hopes for higher marg...
Redeye will likely increase its Base Case and forecasts slightly following a Q4 report coming in som...
Sales and EBITDA inline with pre-announcement 31% organic growth in Technology Estimates likely up 1...
As a result of the earlier trading update, the main interest is in the outlook, especially for the U...
Redeye updates on Evolution post Q4-results which came in close to our forecasts.
Redeye comments on Coala-Life’s latest development: the company has secured liquidity of cSEK27m thr...
Redeye was impressed by yet another solid quarter from new-old CEO, Anders Lidbeck, who once again b...
Redeye updates its estimates and valuation following Vitec’s Q4 2023 report, featuring solid top-lin...
Redeye comments on the public offering announced today.
Redeye leaves its comments on today's news that Acarix has appointed a new CEO.
Redeye is neutral about the return of the lipodystrophy project, as it does not affect our base case...
Redeye comments on Hoylu’s Q4 2023 report, with figures missing our expectations across the board.
Redeye endorses Iconovo’s new order from a Top-10 pharma company to evaluate a multi-dose inhaler fr...
DT’s Q4 results were somewhat better than estimated.
